Indivior Plc (INDV)

Mar 4, 2025, 8:40 AM EST - 5 weeks ago

Indivior Announces Further Changes to Board of Directors

Feb 27, 2025, 2:48 AM EST - 5 weeks ago

UK's Indivior appoints Joe Ciaffoni as CEO

Feb 27, 2025, 2:00 AM EST - 5 weeks ago

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Feb 24, 2025, 2:00 AM EST - 6 weeks ago

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Feb 20, 2025, 2:26 PM EST - 6 weeks ago

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:13 PM EST - 6 weeks ago

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Feb 20, 2025, 2:55 AM EST - 6 weeks ago

UK's Indivior forecasts 17% decline in 2025 revenue

Feb 20, 2025, 2:00 AM EST - 6 weeks ago

Indivior Announces FY and Q4 2024 Financial Results

Feb 12, 2025, 2:00 AM EST - 2 months ago

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Nov 19, 2024, 12:52 PM EST - 5 months ago

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Nov 7, 2024, 2:24 PM EST - 5 months ago

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Oct 30, 2024, 12:30 PM EDT - 5 months ago

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Oct 24, 2024, 2:02 PM EDT - 5 months ago

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 2:00 AM EDT - 6 months ago

Indivior Announces Q3 2024 Financial Results

Oct 13, 2024, 10:00 AM EDT - 6 months ago

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Oct 10, 2024, 7:33 AM EDT - 6 months ago

British drugmaker Indivior cuts 2024 revenue forecast, shares fall

Oct 10, 2024, 7:00 AM EDT - 6 months ago

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Oct 7, 2024, 11:30 AM EDT - 6 months ago

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Sep 29, 2024, 6:01 PM EDT - 6 months ago

INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Sep 29, 2024, 11:00 AM EDT - 6 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Affected Investors Are Encouraged To Lend A Hand To The Schall Law Firm

Sep 27, 2024, 11:00 AM EDT - 6 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Investors Are Urged To Assist The Schall Law Firm

Sep 25, 2024, 11:00 AM EDT - 7 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

Sep 24, 2024, 1:07 PM EDT - 7 months ago

Investors in Indivior PLC Should Contact The Gross Law Firm Before October 1, 2024 to Discuss Your Rights – INDV

Sep 23, 2024, 11:00 AM EDT - 7 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

Sep 23, 2024, 7:13 AM EDT - 7 months ago

Top 3 Health Care Stocks That May Explode This Month

MRNA PGNY

Sep 21, 2024, 11:00 AM EDT - 7 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Sep 19, 2024, 11:00 AM EDT - 7 months ago

Indivior PLC Is Being Sued For Violating Securities Regulations And Shareholders Are Invited To Contact The Schall Law Firm

Sep 17, 2024, 11:00 AM EDT - 7 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm